These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9154271)

  • 1. Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect.
    Bito LZ
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S1-14. PubMed ID: 9154271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin derivates as ocular hypotensive agents.
    Alm A
    Prog Retin Eye Res; 1998 Jul; 17(3):291-312. PubMed ID: 9695796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ocular effects of prostaglandins and the therapeutic potential of a new PGF2 alpha analog, PhXA41 (latanoprost), for glaucoma management.
    Bito LZ; Stjernschantz J; Resul B; Miranda OC; Basu S
    J Lipid Mediat; 1993; 6(1-3):535-43. PubMed ID: 8358014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients.
    Chiba T; Kashiwagi K; Kogure S; Abe K; Shibuya T; Furuichi M; Iijima H; Tsukahara S
    J Glaucoma; 2001 Oct; 10(5):406-10. PubMed ID: 11711839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin-induced iridial pigmentation in primates.
    Selén G; Stjernschantz J; Resul B
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S125-8. PubMed ID: 9154288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.
    Wistrand PJ; Stjernschantz J; Olsson K
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S129-38. PubMed ID: 9154289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost.
    Chiba T; Kashiwagi K; Ishijima K; Furuichi M; Kogure S; Abe K; Chiba N; Tsukahara S
    Jpn J Ophthalmol; 2004; 48(2):141-7. PubMed ID: 15060793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study.
    Chiba T; Kashiwagi K; Chiba N; Ishijima K; Furuichi M; Kogure S; Abe K; Tsukahara S
    Br J Ophthalmol; 2003 Aug; 87(8):956-9. PubMed ID: 12881333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latanoprost as a new horizon in the medical management of glaucoma.
    Stjernschantz J; Alm A
    Curr Opin Ophthalmol; 1996 Apr; 7(2):11-7. PubMed ID: 10163315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histology and fine structure of the iris and outflow system following latanoprost therapy.
    Grierson I; Pfeiffer N; Cracknell KP; Appleton P
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S176-84. PubMed ID: 12204715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of early change in iris color with latanoprost use.
    Pappas RM; Pusin S; Higginbotham EJ
    Arch Ophthalmol; 1998 Aug; 116(8):1115-6. PubMed ID: 9715697
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased iris pigment in a child due to latanoprost.
    Brown SM
    Arch Ophthalmol; 1998 Dec; 116(12):1683-4. PubMed ID: 9869807
    [No Abstract]   [Full Text] [Related]  

  • 13. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study.
    Alm A; Villumsen J; Törnquist P; Mandahl A; Airaksinen J; Tuulonen A; Marsk A; Resul B; Stjernschantz J
    Ophthalmology; 1993 Sep; 100(9):1312-6; discussion 1316-7. PubMed ID: 8371917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of prostaglandin analogues in glaucoma.
    Lindén C
    Expert Opin Investig Drugs; 2001 Apr; 10(4):679-94. PubMed ID: 11281818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin analogs in the treatment of glaucoma.
    Hejkal TW; Camras CB
    Semin Ophthalmol; 1999 Sep; 14(3):114-23. PubMed ID: 10790575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
    Takagi Y; Nakajima T; Shimazaki A; Kageyama M; Matsugi T; Matsumura Y; Gabelt BT; Kaufman PL; Hara H
    Exp Eye Res; 2004 Apr; 78(4):767-76. PubMed ID: 15037111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment.
    Greve EL; Rulo AH; Drance SM; Crichton AC; Mills RP; Hoyng PF
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S89-92. PubMed ID: 9154282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue.
    Diestelhorst M; Krieglstein GK; Lusky M; Nagasubramanian S
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S77-81. PubMed ID: 9154280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change.
    Grierson I; Lee WR; Albert DM
    Arch Ophthalmol; 1999 Mar; 117(3):394-6. PubMed ID: 10088822
    [No Abstract]   [Full Text] [Related]  

  • 20. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents.
    Hoyng PF; Rulo A; Greve E; Watson P; Alm A
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S93-8. PubMed ID: 9154283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.